ClinicalTrials.gg
Drug

Upadacitinib clinical trials

Also written RINVOQ and ABT-494.

studies test it
98
open now
36
in phase 3
46
first study started
2012

How each study uses upadacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the upadacitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Aug 2019 · RINVOQ · NDA 211675 (FDA, Drugs@FDA)
European Union
16 Dec 2019 · Rinvoq · EMEA/H/C/004760 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Upadacitinib
77
Upadacitinib 15 MG
7
Upadacitinib (ABT-494)
3
Upadacitinib 30mg Dose
2
Upadacitinib 15 MG [Rinvoq]
2

Brand

RINVOQ
56
RINVOQ LQ
1

Development codes

ABT-494
47

Studies by the year they started

97 studies that test it; most in 2026 (19); 1 more planned to start later

Studies that test upadacitinib, by start year
YearStudies
20121
20131
20142
20152
20167
20176
20188
20197
20205
20213
20222
202311
202413
202510
202619

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
9
Phase 2
27
Phase 3
46
Phase 4
18
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 64 · Other 34

AbbVie (60) · Sixth Affiliated Hospital, Sun Yat-sen University (5) · Peking University People's Hospital (3) · University of California, San Francisco (2) · CARE ARTHRITIS LTD. (2) · Berinstein, Jeffrey (2) · Tianjin Medical University (1) · Peking Union Medical College (1)

Often tested with

Tested in the same studies.

Tofacitinib (5) · Secukinumab (4) · Elsubrutinib (4) · Adalimumab (3) · ABBV-722 (3) · Baricitinib (3) · Ixekizumab (3) · Ustekinumab (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 18, 8 in phase 3

Studies that test upadacitinib, phase 3 first.

Studies

Open first, then newest update. How each study uses upadacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 98

See all 98 studies that test upadacitinib →

Given beside what is tested · 3 — upadacitinib is usual care or a partner of the new treatment

Codes

What other systems call upadacitinib · ClinicalTrials.gg INT000588

  • MeSH (NLM) C000613732upadacitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 4RA0KN46E0UPADACITINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2196092Confirmed FDA, Wikidata
  • Wikidata Q27074125upadacitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152802UpadacitinibOne source FDA
  • DrugBank DB15091One source Wikidata

Also registered as upadacitinib hemihydrate (UNII NEW4DV02U5).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.